



Procalcitonin (PCT)

# Effective management of surgical site infections

B·R·A·H·M·S PCT: Superior to CRP  
in identifying infections

# Surgical site infection (SSI)

## The global burden of post-operative infections

SSIs are among the most common healthcare-associated infections (HAI). They are connected with<sup>1</sup>



longer post-operative hospital stays



additional surgical procedures



treatment in intensive care units



higher mortality

Up to **10%**  
of surgical patients in the EU  
are likely to develop SSIs,  
depending on the type of  
surgical procedure<sup>1</sup>

**500,000**

people per year are affected  
by SSI in Europe<sup>2</sup>

**~1/10**

people who have surgery  
in Low and Middle Income  
Countries acquire a SSI<sup>2</sup>

**2–5%**

of patients undergoing inpatient  
surgery develop a SSI in the US<sup>3</sup>

**~7–10**

additional postoperative  
hospital days in the US<sup>3</sup>

**2–11**

times higher risk of death  
compared with operated patients  
without a SSI in the US<sup>3</sup>

**up to 20%**

of caesarean section procedures in  
Africa lead to a wound infection<sup>2</sup>



**11,000–35,000**

estimated cost per SSI in the US<sup>4</sup>

# Identify SSIs early


## PCT supports detection of infectious complications after surgery

PCT (procalcitonin) is a biomarker that provides insights into the risk of a patient having a bacterial infection, as well as the severity of that infection. The laboratory test **Thermo Scientific™ B·R·A·H·M·S PCT™** supports earlier and better diagnosis, clinical decision making for systemic bacterial infections and therapy control due to its following main characteristics:<sup>5,6,7</sup>

- **High sensitivity and specificity for bacterial infection**
- **Fast increase after bacterial infection** within 3–6 hours (faster than CRP)
- **Assessment of disease severity, prognosis and antibiotic stewardship**

Independent of an infectious process, the PCT level can be slightly elevated shortly after multiple trauma or major surgery. It peaks on the first or second day after surgery and returns to baseline. In case, if there is a higher increase in PCT level or if there is a second peak, this could be a likely indication of an infectious complication.<sup>8</sup>

An early increase of PCT after surgery allows detection of SSI before clinical signs become evident.



**Figure 1.** PCT in patients after major aortic surgery with infection (n=67) and without infection (n=209) over the days before and after surgery<sup>9</sup>

Serial PCT measurements can help to differentiate postoperative infectious complications from a transient unspecific PCT rise due to surgical trauma.<sup>8</sup>

# PCT is superior to CRP

## Identifying infections with high accuracy



### Bacterial infection

Unspecific induction due to surgery or trauma is lower and shorter for PCT compared to CRP due to higher specificity to bacterial infection and faster kinetics.<sup>6</sup>

PCT levels increase significantly higher in patients with sepsis, or septic shock and also in non-survivors than in survivors in contrast to CRP.<sup>10</sup>

Compared with CRP the rise of PCT levels has a higher specificity for bacterial infection and is less impacted by non-infectious surgery- or trauma-associated inflammation.<sup>11</sup>





Figure 2. Comparison of PCT and CRP in the control (n=84) and infection groups (n=16) after cardio-pulmonary bypass<sup>10</sup>

# PCT-aided antibiotic therapy

## Reducing antibiotic exposure, ICU days, and costs




**-60%**

prescribed antibiotics in patients after open heart surgery<sup>12</sup>

Without negative impact on clinical outcome (morbidity or mortality)<sup>12</sup>

**Figure 3.** Antibiotic prescription (% of patients) after open heart surgery in control group vs. PCT group (discouraging antibiotic use in patients with PCT  $< 0.5 \mu\text{g/L}$ ) in addition to clinical symptoms (n=205)<sup>12</sup>



**-12%**

ICU days<sup>13</sup>

**-25%**

ABx days in surgical ICU patients<sup>13</sup>

Without negative impact on clinical outcome<sup>13</sup>

**Figure 4.** Duration of ICU stay and of antibiotic therapy in surgical intensive care patients receiving antibiotic therapy aided by PCT algorithm after confirmed or high-grade suspected infections (n=110) (ABx days = days of antibiotic therapy)<sup>13</sup>

PCT-aided antibiotic stewardship algorithm can help reduce the antibiotic exposure in surgical patients.

# Intra-abdominal infectious complications

## Utility of PCT for antibiotic (ABx) and surgical decisions

### Secondary peritonitis

**50% relative reduction in ABx duration**

in patients undergoing surgery for secondary peritonitis<sup>14</sup>

### Acute pancreatitis

**-17% ABx initiation<sup>15</sup>**

**-32% ABx treatment<sup>16</sup>**

**-25% ICU days<sup>16</sup>**

**-12% hospitalization costs<sup>16</sup>**


in patients with severe acute pancreatitis

### Appendicitis

**89% sensitivity**

**90% specificity**

for diagnosis of complicated appendicitis in children<sup>18</sup>



### Anastomotic leakage

**NPV  $\geq$  99%**

in excluding anastomotic leaks (AL) after a colorectal resection: combination of PCT, CRP and Dutch Leakage Score (DLS) allows the exclusion of AL in the early postoperative period<sup>19</sup>

### Diverticulitis

**PCT  $>$  0.1  $\mu$ g/L**

indicates complicated diverticulitis which needs ABx therapy<sup>17</sup>

# Cardiac surgery

## PCT predicts infection with good sensitivity and specificity


**81% sensitivity**  
**82% specificity**

to identify postoperative infections in cardiac surgery patients → helps avoid unnecessary ABx in non-infected patients<sup>20</sup>




**Better precision than CRP and IL-6**

Postoperative increased serum PCT levels predict infection more precisely than CRP<sup>21</sup> and IL-6<sup>22</sup>



**Figure 5.** Trends in PCT and CRP levels in infected vs. non-infected patients with Delayed Sternal Closure (n=27).<sup>21</sup> The difference in PCT levels was significant between the infected vs. non-infected patients from POD2 onwards ( $p < 0.05$ ).



**Figure 6.** Comparison of PCT and IL-6 in patients undergoing aortic surgery (n=35)<sup>22</sup>

After cardiac surgery, the transient rise of PCT without infectious complications usually happens within 24 hours. (Figures 5 and 6).<sup>21,22</sup>


Meta-analysis of 34 studies of PCT after cardiac surgery revealed that cut-off points for discriminating infection depend on the surgical procedures and on intra-operative events.<sup>23</sup>

**Thus, the dynamics of PCT levels over time may be more important than absolute values.**

# Severe burns


## Prognostic power in high inflammatory state

Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick diagnosis and patient stratification, early and appropriate antimicrobial therapy, and focus control are crucial for patients' survival.



PCT parallels the **evolution of the infectious process**<sup>24</sup>

**Figure 7.** Line plots of PCT levels evolution along the first week of hospitalization in 101 patients. Differences between PCT levels of patients from the survivor and non-survivor groups are statistically significant ( $p < 0.001$ ).<sup>24</sup>



PCT reflects the **efficacy of antimicrobial therapy**<sup>24</sup>

**Figure 8.** Line plots of PCT levels evolution in the first 15 days of antimicrobial therapy in 101 patients. In non-survivors the PCT levels were significantly elevated from the beginning, with further increase during the last days of life. In the survivor group, PCT levels declined rapidly and remained low.<sup>24</sup>


### Serial PCT measurements can help to

- monitor the efficacy of antimicrobial therapy, allowing faster de-escalation or stop without increasing mortality
- stratify patients who need more intensive care
- predict outcomes



# Post-transplantation

## Rejection or infection?



**Figure 9.** Mean serum values of PCT and CRP in 25 lung transplantation patients with or without infection or with rejection over time<sup>25</sup>

### Lung transplant



### High specificity

in detecting infectious complications in patients after lung transplantation<sup>25</sup>

In cases of rejection or primary graft dysfunction (PGD) grade 1 & 2, PCT remains low, thus allowing for differentiation from infection<sup>25</sup>

### Liver transplant



**Pre-transplant serum PCT >0.5 µg/L indicates the likelihood of infection**

in patients undergoing living donor liver transplantation (LDLT)<sup>26</sup>

Patient should be re-evaluated regardless of systemic symptoms

Rescheduling of liver transplant should be considered


An infection, but not rejection, causes an early and dramatic increase in PCT and allows the identification of infectious complications in contrast to CRP.<sup>25,27</sup>

# Multiple trauma

## Prediction of post-traumatic MODS


Multiple organ failure is a major cause of morbidity in blunt multiple traumas patients.

The evaluation of clinical condition and the identification of patients at risk after multiple trauma is one of the biggest problems in multiple trauma therapy.



PCT is useful in **early identification of high risk patients** who could develop post-traumatic Multi Organ Dysfunction Syndrome (MODS)<sup>28</sup>

Figure 10. PCT showed significantly higher levels in patients developing MODS (n=21) compared with patients not developing MODS (n=73)<sup>28</sup>



The increase of PCT plasma levels precedes the clinical diagnosis of sepsis and MODS **up to 3 days**<sup>28</sup>

Figure 11. PCT showed higher levels in patients developing sepsis (n=15) compared with patients not developing sepsis (n=79)<sup>28</sup>

In trauma patients, initial peak PCT levels may be used as an early predictor of severity of injury, development of sepsis and Multi Organ Dysfunction, and mortality. Serum PCT levels may contribute to the identification of patients who may benefit most from more aggressive management.<sup>29</sup>



B·R·A·H·M·S  
**PCT**

The power of PCT  
allows to

**Early identify**  
surgical site infections

**Safely reduce**  
antibiotic exposure

**Confidently secure**  
treatment decisions

**Fewer**  
systemic  
complications  
from infection



**Lower**  
incidence  
of sepsis



**Shorter**  
duration of  
antibiotic  
treatment



**Shorter**  
length of  
hospital stay



## B·R·A·H·M·S PCT

### Secured clinical decision making independent of platform



B·R·A·H·M·S PCT sensitive KRYPTOR



ALINITY i B·R·A·H·M·S PCT  
ARCHITECT B·R·A·H·M·S PCT



VIDAS® B·R·A·H·M·S PCT



LIAISON® B·R·A·H·M·S PCT II GEN



Lumipulse® G B·R·A·H·M·S PCT



PATHFAST™ B·R·A·H·M·S PCT



VITROS® B·R·A·H·M·S PCT



ELECSYS® B·R·A·H·M·S PCT



ADVIA Centaur® B·R·A·H·M·S PCT  
Atellica® IM B·R·A·H·M·S PCT  
Dimension® EXL™ LOCI™ B·R·A·H·M·S PCT\*

\* coming 2023

Not all intended uses and applications mentioned in this printing are registered for every product in every country.

#### References

1. European Centre for Disease Prevention and Control. Healthcare-associated infections: surgical site infections. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019.
2. World Health Organization. Protocol for surgical site infection surveillance with a focus on settings with limited resources. 2018 (ISBN 978-92-4-156554-7).
3. Anderson et al., Infect Control Hosp Epidemiol 2008; 29(1): 51–61.
4. Scott II, The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention, 2009.
5. Harbarth et al., Am J Respir Crit Care Med 2001; 164: 396–402.
6. Meisner M, Procalcitonin – Biochemistry and Clinical Diagnosis, ISBN 978-3-8374-1241-3, UNI-MED, Bremen 2010.
7. Müller et al., Crit Care Med 2000, 28 (4): 977–983.
8. Meisner et al., Crit Care 2006, 10: R1.
9. Amour et al., Crit Care Med 2008; 36(4): 1147–1154.
10. Jebali et al., Anesthesiology 2007; 107: 232–238.
11. Uzzan et al., Crit Care Med 2006; 34: 1996–2003.
12. Maravić-Stojković et al., Srpski Arhiv za Celokupno Lekarstvo 2011; 139: 736–742.
13. Hochreiter et al., Critical Care 2009, 13: R83.
14. Hunag et al., PLoS One 2014; 9(3): e90539.
15. Siriwardena et al., Lancet Gastroenterol Hepatol 2022; 7(10): 913–921.
16. Qu et al., Saudi Med J 2012; 33(4): 382–387.
17. Jeger et al., Swiss Med Wkly 2017; 147: w14555.
18. Cui et al., Italian Journal of Pediatrics 2019; 45: 78.
19. Italian ColoRectal Anastomotic Leakage (iCraL) Study Group, BJS Open 2020; 4(3): 499–507.
20. Tanaka et al., Journal of Surgery and Science 2014; 2(1).
21. Davidson et al., Pediatr Res 2013; 74(4): 413–419.
22. Reith et al., Dig Surg 1998; 15: 260–265.
23. Sponholz et al., Crit Care 2006; 10: R145.
24. Cabral et al., Burns & Trauma 2018; 6(10).
25. Suberviola et al., PLoS ONE 2017; 12(7): e0180202.
26. Hara et al., Hepatol Res 2018; 48: 383–390.
27. Kuse et al., Int Care Med 2000; 26: 187–192.
28. Haasper et al., Technol Health Care 2010; 18(2): 89–100.
29. AlRawahi et al., Crit Care 2019; 23(1): 390.

#### Clinical Diagnostics

Thermo Fisher Scientific  
B·R·A·H·M·S GmbH  
Neuendorfstr. 25  
16761 Hennigsdorf, Germany

+49 (0)3302 883 0  
+49 (0)3302 883 100 fax  
info.pct@thermofisher.com  
www.thermoscientific.com/brahms

Learn more at [thermoscientific.com/procalcitonin](https://thermoscientific.com/procalcitonin)  
or email us at [info.pct@thermofisher.com](mailto:info.pct@thermofisher.com)



**Not all products are CE marked or have 510(k) clearance for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.**

© 2023 Thermo Fisher Scientific Inc. All rights reserved. B·R·A·H·M·S PCT and all other trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. ADVIA Centaur, Atellica IM, Dimension EXL and LOCI are registered and protected trademarks belonging to Siemens Healthcare Diagnostics. ADVIA Centaur B·R·A·H·M·S PCT, Atellica IM B·R·A·H·M·S PCT, and Dimension EXL LOCI B·R·A·H·M·S PCT are products of Siemens Healthcare Diagnostics licensed from Thermo Fisher Scientific. ALINITY i and ARCHITECT B·R·A·H·M·S PCT are products of Abbott licensed from Thermo Fisher Scientific. Elecsys is a registered and protected trademark belonging to Roche or one of its subsidiaries. Elecsys B·R·A·H·M·S PCT is a product of Roche licensed from Thermo Fisher Scientific. LIAISON is a registered and protected trademark belonging to DiaSorin S.p.A. LIAISON B·R·A·H·M·S PCT II GEN is a product of DiaSorin S.p.A. licensed from Thermo Fisher Scientific. Lumipulse is a registered trademark of Fujirebio Inc. in Japan and in other countries. Lumipulse G B·R·A·H·M·S PCT is a product of Fujirebio Inc. licensed from Thermo Fisher Scientific. PATHFAST is a registered trademark of LSI Medience Corporation and manufactured in Japan. PATHFAST (reagents, accessories and the device) is a product of PHC Europe B.V. and sold via distributors in EMEA. PATHFAST B·R·A·H·M·S PCT is a product of LSI Medience Corporation licensed from Thermo Fisher Scientific. VIDAS is a registered trademark of bioMérieux S.A. or one of its subsidiaries. VIDAS B·R·A·H·M·S PCT is a product of bioMérieux licensed from Thermo Fisher Scientific. VITROS is a trademark of Ortho Clinical Diagnostics. VITROS B·R·A·H·M·S PCT is a product of Ortho Clinical Diagnostics licensed from Thermo Fisher Scientific. Ortho Clinical Diagnostics is a subsidiary of QuidelOrtho Corporation. KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Patents: [www.brahms.de/patents](http://www.brahms.de/patents). 106964.6